CLINICAL_TRIALS
trial_result
· 2020-12-22
Clinical Trial Update: Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) [Phase 2]
Summary
A Phase 2 trial evaluated pimavanserin as an adjunctive treatment for negative symptoms in schizophrenia; results completed and posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2020-12-22